Connect with us

Cannabis News

Bipartisan Congressional Lawmakers Give Mixed Reactions To Marijuana Rescheduling News From Trump Administration

Published

1 month ago

on

Bipartisan congressional lawmakers are making a potentially immediate decision President Donald Trump to move forward with federal marijuana overhaul—Democrats like Rep. Alex Ocasio-Cortez (D-NY) call the reform a “no” and others like Rep. Andy Harris (R-MD) have pushed back against the proposal.

It was first reported on Thursday that Trump plans to sign an executive order on the reorganization, possibly directing the attorney general to complete the process started by the Biden administration to reclassify cannabis under Title III of the Controlled Substances Act (CSA).

Since then, several lawmakers from both sides of the aisle have weighed in on the plan in interviews with Marihuana Moment. While Democrats may disagree with the president on many policy issues, they have generally welcomed news of the restructuring’s development, though they would eventually like to see the federal ban end entirely rather than increase change.

Ocasio-Cortez said it was a “no brainer” to implement the policy change, which would legalize marijuana but remove some barriers to research and allow cannabis businesses to take a federal tax deduction, symbolically recognizing the plant’s medical value.

“I have honestly felt that it has been a race between the two major parties to get reform,” said the congressman. “I mean, it’s inevitable, so of course I’m all for that move.”

Asked about reports that House Speaker Mike Johnson (R-LA) told Trump not to reschedule, Ocasio-Cortez said an executive order would bypass lawmakers who oppose it. The speaker “has no pen” in such orders, he said.

“If he wants to try to pass some legislation and push his entire Republican team to do that, I think that’s within his power,” the congressman said.

Rep. Ilhan Omar (D-MN), co-chair of the Congressional Cannabis Caucus, told Marihuana Moment that while it’s true that Trump plans to advance rescheduling, that would be a “game changer” and a “huge” accomplishment.

However, he said that it is difficult for any member of parliament to take his word seriously, “because the president has often changed his position on various policy issues in the past. “I hope (he will act on the rescheduling) and it will come true,” he said.

Rep. Dina Titus (D-NV), another co-chair of the Congressional Cannabis Caucus, told Marijuana Moment that “Trump’s proposal would be a positive step toward cannabis policy reform, but more work remains.”

“While it would ease restrictions on medical cannabis research and alleviate some of the tax burden on state illegal cannabis businesses, classifying marijuana as a Schedule III substance still allows for the unfair and disproportionate incarceration of recreational users and limits access to banking services for cannabis businesses,” he said. “We must continue to address the systemic inequality associated with scheduling cannabis as a dangerous drug.”

House Majority Leader Steve Scalise (R-LA), for his part, did not weigh in on the merits of the reconsideration proposal, but told Marijuana Moment that he was with the president Thursday afternoon and “didn’t hear that” about plans to end the reform process.

One of the House’s most outspoken anti-marijuana lawmakers, Rep. Andy Harris (R-MD), insisted that he doesn’t “agree with everything the president does, and I don’t.” He also appears to question the veracity of recent reports about the imminence of a restructuring move, stating that he was told “for sure” it would happen on Thursday, which did not materialize.

There have been mixed reports on the timing of a possible reconsideration action, with some sources still hopeful it will happen on Friday, CNBC to report that the executive order would be issued on Monday of next week and as early as Axios to report that the reform is expected to come early next year.

Rep. Richard Hudson (R-NC), chairman of the National Republican Congressional Committee (NRCC), told Marihuana Moment that rescheduling is a “terrible idea” and noted that he had never discussed the issue with the House Speaker.

In a statement Friday, Sen. Kirsten Gillibrand (D-NY) said she was “encouraged to see the first move by the Drug Enforcement Administration under President Biden to reorganize marijuana, and I urge President Trump to continue that effort.”

“Common sense tells us that marijuana should not be in the same category as deadly drugs like heroin, and reclassifying it is a small step forward in creating economic opportunity, supporting research into the medical benefits of marijuana, and increasing public safety,” he said. “However, much more work remains to be done. I will continue to advocate for the complete decriminalization of marijuana and the expungement of the records of Americans convicted of marijuana possession.”

Rep. Ted Lieu (D-CA) reacted to the news by criticizing the Biden administration after it “failed” to complete marijuana rescheduling, and said he hopes the Trump administration doesn’t make the “same mistake.”

Meanwhile, Trump’s former White House press secretary, Sean Spicer, discussed the news development on an episode of his “The Huddle” podcast on Friday and said Trump’s potential reshuffle action, like other policy issues, “comes back to power and money.”

“There are a lot of people who instinctively think it’s a good play with young voters,” he said. “The bottom line, this whole reclassification, really comes down to the financial part of this.”

Spicer added that there is a “bank part” because cannabis companies have long faced a federal ban on accessing banking services, regardless of state laws. However, it inflated the impact of the reorganization on that issue, because placing marijuana in Schedule III of the CSA would not make it federally legal, so some banks would likely continue to avoid serving the marijuana industry even if this modest reform were enacted.

“It’s a big business with a lot of money, and I have to believe that’s what it really comes down to,” he said. “The president is not running for re-election … there are a lot of people who will not be happy about this. I am one of them.”




“You walk through downtown (Washington, DC) or any city, it smells like pot and piss,” he added. “I think, given where we are as a society, the last thing we need to do is make drugs more accessible. I don’t think it’s a good idea, but I’ll tell you, I think where people are missing the story is: Follow the money.”

Trump said this in mid-August he would make the reorganization decision in a week. But despite the growing timeline and rumors, a White House spokesperson told Marihuana Moments on Thursday that “no final decision has been made on rescheduling marijuana.”

The Washington Post reported Thursday afternoon that Trump planned to issue an executive order to federal agencies to move ahead with cannabis rescheduling.

The outlet also said the president met with marijuana industry executives Robert F. Kennedy Jr. earlier this week in the Oval Office. with Secretary of Health and Human Services and Centers for Medicare and Medicaid Services Administrator Mehmet Oz. During that meeting, Trump called Johnson, the House Speaker, who spoke out against the cannabis redistricting,

If the administration ultimately enacts the rescheduling, it would mark one of the most significant developments in federal marijuana policy since its prohibition half a century ago, when it was banned under Article III. With a reclassification, marijuana has medical value and a lower abuse potential compared to Schedule I drugs like heroin.

—
It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.

Learn more about our marijuana bill tracking and become a Patreon supporter to gain access
—

Trump endorsed the rescheduling — as well as an initiative to legalize access to industrial banking and adult use in Florida — on the campaign trail. The president had been silent on the issue since taking office for a second term, until a meeting in August where, in response to a reporter’s question, he announced that the administration would decide to reschedule in a few weeks.

The possibility of an immediate rescheduling announcement comes a few weeks later the president signed a major spending bill that would effectively ban most consumer hemp productsdrawing criticism from hemp industry players who say the policy change would wipe out the market.

LCB Contributed reporting from Washington DC

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Related Topics:
Continue Reading

Cannabis News

Vivent Biosignals & Green Laniel join forces to bring plant-driven agriculture to the US

Published

19 hours ago

on

January 17, 2026

By











Vivent Biosignals and Green Laniel Consulting have announced a partnership to accelerate plant-driven irrigation and irrigation in key U.S. agricultural markets. Green Laniel Consulting is a US-focused provider of agronomic solutions led by Mauricio Manotas.

By combining Vivent’s ability to decode plant biosignals in real-time using plant biosensors, machine learning and AI with Green Laniel’s deep experience in agronomy, grower operations and US market access, the partnership allows growers to make decisions based on what really matters: how the plant itself is responding.

© Vivent Biosignals

The partnership will cover a variety of crops and production systems, initially plant-driven irrigation and greenhouses for perennial crops, including potatoes, directly guided by plant feedback.

“By combining Vivint’s plant-level intelligence with Green Laniel’s strong presence and agronomic leadership in the US, we are enabling a new generation of plant-driven farming systems. This partnership helps growers improve yields and quality while significantly increasing resource efficiency and sustainability.” says Mauricio Manotas, Green Laniel Consulting.

For more information:
Vivent Biosignals
Tel.: +41 79 5114627
Email: (email protected)
https://vivent-biosignals.com/



Publication date:













Continue Reading

Cannabis News

Indiana Lawmakers Approve Bill To Restrict And Regulate Hemp THC Products

Published

20 hours ago

on

January 17, 2026

By

“In India, we would like some certainty about these products so that those who manufacture and sell them know what our laws are.”

By Leslie Bonilla Muñiz, Indiana Capital Chronicle

Indiana lawmakers want state legislation to join the recently enacted federal ban on intoxicating and synthetic hemp products to counter the growing delta-8 industry.

Lengthy and complex legislation would also regulate less potent products that pass statutory muster.

But, “there will be no demand” for products below the proposed threshold, said Justin Swanson, representing the Midwest Hemp Council and 3Chi, a THC products retailer.

THC is the active ingredient in marijuana.

Sen. Aaron Freeman, R-Indianapolis, admitted to the committee that he would prefer to “wipe all these things off the planet, period,” but that his proposal is “whatever is possible.”

His Senate Bill 250 would mimic Congress’s shutdown of what Freeman described as the “Farm Bill loophole,” referring to 2018 legislation that defined legal hemp as any part of the plant that contains less than 0.3 percent delta-9 THC by dry weight. That definition allowed products containing delta-8, THCA and other intoxicating cannabinoids to proliferate, including in Indiana.

A federal funding law passed in November specifies that all types of THC count. It also limits THC products to just 0.4 milligrams per container, and completely bans those made in labs.

“I think (that’s) what the federal government wanted when they passed the Farm Bill in 2018; I think that’s what everybody had in mind when they copied that language here in Indiana,” said Chris Daniels, chief traffic safety resource attorney for the Indiana Prosecuting Attorneys Council. “The target was very low potency THC.”

An industry group supported the changes.

“It is imperative that Indiana act to align with federal policy in the 2026 legislative session,” said Cory Harris, representative of the American Cannabis and Hemp Trade Association. “Failure to do so means that Indiana’s policy will be stricter than federal law, making Indiana a legal cannabis market.”

The federal provisions will go into effect in November. Freeman’s bill repeats those provisions, but puts them into effect four months earlier, in July.

“It’s sweet that Indiana codified a federal law that will decimate an entire industry in the state,” Swanson said. “The landscape is still unsettled.”

U.S. Rep. Jim Baird — a Republican representing Indiana — introduced a proposal to push the effective date of the federal ban to 2028. President Donald Trump also signed an executive order to expedite the reclassification of marijuana as a less dangerous and less restricted drug.

Swanson said his clients support a “responsible regulatory framework,” and told lawmakers that “the status quo is not acceptable to anyone.”

Freeman’s invoice spends dozens of pages specifically regulating low-THC “hemp-derived cannabinoid products” that would be legalized, primarily with a long-standing 21-and-over requirement.

It also puts the Indiana Alcohol and Tobacco Commission in charge of regulating the rest of the industry, establishing four types of licenses for manufacturers, distributors, retailers and carriers. They would be prohibited from advertising within 1,000 feet of schools, playgrounds and others, with retailers prohibited from operating within the same radius.

Retailers would not be able to deliver products or allow customers to consume them on the spot. Selling the products online would also be illegal, another sticking point for advocates.

Dave Colt, CEO and co-founder of Sun King Brewery, said his homegrown company spent months and more than $100,000 on equipment, research and development for its THC seltzer. Amid declining alcohol sales nationwide, seltzers have allowed Sun King to retain its employees and even grow.

“We also make products for at least a dozen Hoosier small businesses. Without that additional revenue, we would be forced to lay off people and reduce our business significantly,” Colt stated. “We believe the industry wants clear regulations to meet consumer demand.”

Other provisions relate to packaging, labeling and testing.

A fiscal impact study by the nonpartisan Service Agency estimated a financial impact of half a billion dollars annually for ATC to administer and enforce the proposal. The agency will have to hire at least one excise officer in each of the six districts plus Marion County to investigate complaints related to the new regulatory framework.

There will be additional costs for law enforcement training, procurement and online databases, the analysis noted.

The costs could be offset by the permit and other fees collected. The measure would allocate 70 percent of the proceeds to ATC administrative efforts, 20 percent to enforcement, 5 percent to the state’s 988 suicide and crisis hotline and 5 percent to the general fund.

If all tobacco sales certificate holders applied for a retail permit, for example, their application fees would generate $2.1 million. If all are approved, the state would earn an additional $4.6 million, according to LSA’s analysis.

The state seed commissioner would handle licensing for hemp growers and handlers.

Freeman also included a sentence that prevents the Indiana code from immediately reflecting the federal reclassification of marijuana, if that goes forward.

“This bill simply says that we’re not going to automatically follow what the federal government does, that we, the 150 of us, would make that decision, not the federal government for us,” Freeman told his colleagues.

The Senate Commerce and Technology committee also approved an amendment to eliminate an excise tax, as all revenue-raising provisions must be initiated in the House.

The revised legislation passed on a 7-2 party line vote, but the next bill must pass through the Senate Appropriations Committee before going to the House floor.

Previous efforts to ban and regulate intoxicating hemp products have failed.

Asked about his chances this year, Senate Republican Leader Rodric Bray told reporters, “I don’t have that crystal ball,” but added, “I think the bill is in pretty good shape right now.”

“I think in Indiana, we would like some certainty about these products, so that those who manufacture and sell them know what our laws are,” he continued, “and, most importantly, to build in some really meaningful protections for our young people across the state.”

This story was first published by the Indiana Capital Chronicle.

Brendan Cleak’s photo.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Creating a thoughtful cannabis environment for Colorado Springs

Published

2 days ago

on

January 16, 2026

By

In Colorado Springs, where the landscape of legal cannabis is centered around medical use, BioMeds Weed Dispensary Colorado Springs has become a destination for patients seeking high-quality cannabis products and a fair and respectful retail experience. Located at 2301 Rand Avenue, BioMeds has developed a reputation for prioritizing product integrity, patient education and consistent service in response to the brightest trends found in recreationally oriented markets.

Unlike recreational dispensaries, where the volume and variety can sometimes overwhelm, BioMeds takes a deliberate approach. The dispensary offers a good selection of medical cannabis products, including a variety of delivery formats to suit your health needs. These typically include flower strains, tinctures, capsules, topicals, and ingestibles, allowing patients to explore therapeutic cannabis without relying on inhaled methods.

BioMeds understands that patients arrive with different experiences, preferences and conditions. To meet these needs, the dispensary emphasizes informed, non-judgmental customer service based on product knowledge. The staff is trained to explain how different formats work, as well as interpret cannabinoid ratios, identify common terpenes, and select products that match specific wellness goals.

© BioMeds Weed Dispensary Colorado Springs

BioMeds’ product selection is part of the reason patients turn to cannabis. For many, whole flower remains a must-have choice, especially strains that emphasize CBD content, balanced proportions or effect-specific terpene profiles. BioMeds often sells indica, sativa, and hybrids with specific labeling, allowing patients to make informed decisions about onset time, duration, and expected outcome. Beyond flower, tinctures and capsules offer discreet, dose-controlled ways to incorporate cannabis into your daily wellness routine, especially for those managing pain, inflammation, or neurological conditions.

Topicals are also a key part of BioMeds’ offering. These include cannabinoid-infused creams, salves, and lotions intended for topical use. Patients dealing with joint discomfort, muscle tension, or skin conditions often turn to topical products for their non-toxic effects and targeted relief. These products also serve as an entry point for patients exploring cannabis for the first time, especially when faced with systemic or psychoactive effects.

Another category that sees sustained interest in BioMeds is ingestion. These may include low-dose edibles, oils, or beverages tailored to patients seeking long-lasting, absorbed beverages. While recreational edibles in Colorado may gravitate toward high-THC formats, medically focused dispensaries like BioMeds ensure that low-dose, balanced-ratio, CBD-rich formats are available and clearly labeled. Many patients prefer longer-lasting edible formats, especially for managing symptoms at night or for relief throughout the day.

Compliance is a pillar of BioMeds’ operating philosophy. As a medical-only dispensary, the group complies with all Colorado Department of Public Health and Environment (CDPHE) guidelines. Patients must present a valid marijuana card, and all transactions are recorded and monitored according to state protocols. BioMeds does not allow recreational sales and maintains internal training programs to keep employees up-to-date on evolving regulations, labeling requirements and patient protection.

While the dispensary may not offer flashy promotions or themed events often seen in the recreational market, it has placed a special emphasis on medical integrity and personalized service in the Colorado Springs cannabis landscape. For patients who prioritize results over hype, BioMeds offers a consistent experience with proven products and a team that truly understands the nuances of using medical cannabis.

Behind the scenes, BioMeds maintains strong supplier relationships to ensure product availability and freshness. Inventory is regularly reviewed and rotated, and the team communicates directly with manufacturers to maintain transparency around sourcing, testing and packaging. The dispensary favors small and medium-sized Colorado growers who focus on consistency and compliance, with many products undergoing third-party lab testing for cannabinoid content, residual solvents and microbial contamination.

For more information:
BioMeds Weed Dispensary Colorado Springs
biomedsofcolorado.com/

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media